Monopar Therapeutics — Director's Dealing 2026

Jan 30, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-01-28

Reporting Person: Robinson Chandler (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-28	Common Stock	J	62815	—	Acquired	62815	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	85718	Direct

Footnotes

F1: Pro rata liquidating distribution from Tactic Pharma, LLC ("Tactic"), of which the reporting person is a non-controlling member. In prior reports, the reporting person reported beneficial ownership of 272,026 shares of Monopar Therapeutics Inc. common stock held by Tactic.

F2: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.